Safety Profile of Upadacitinib over 15 000 Patient-years Across Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Atopic Dermatitis

Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.

Several safety risks have been associated with JAK inhibitor use, and recent data from the ORAL Surveillance study have highlighted the need to further characterise the safety profile of these drugs. To this end, Burmester, et al. evaluated the long-term safety profile for upadacitinib, based on more than 6000 patients and 15 000 patient-years of exposure.